Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.32 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10161479 | 0.83 | TSHR (0.40) | TSHRSMN1; SMN2MAPTFAAHKDM4E | |
| SCHEMBL14397823 | 0.78 | PHF8 (0.50) | TSHRSMN1; SMN2MAPTKDM4EKDM5C | |
| SCHEMBL16566001 | 0.77 | MAPT (0.54) | TSHRSMN1; SMN2MAPTFAAHKDM4E | |
| SCHEMBL13196353 | 0.76 | TSHR (0.39) | TSHRSMN1; SMN2MAPTFAAH | |
| SCHEMBL17793319 | 0.76 | — | — | |
| SCHEMBL12838131 | 0.74 | LMNA (0.43) | TSHRSMN1; SMN2MAPTFAAHKDM4E | |
| SCHEMBL14391566 | 0.74 | ALDH1A1 (0.46) | TSHRSMN1; SMN2MAPTFAAHKDM4E | |
| SCHEMBL11959163 | 0.72 | TSHR (0.48) | TSHRSMN1; SMN2MAPTFAAH | |
| SCHEMBL7871513 | 0.71 | — | — | |
| SCHEMBL871580 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | SYNTONIX PHARMACEUTICALS, INC. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059889-A1 | PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn | FCGRT, FCGR3B, FCGR1A | TSHR 509/4885SMN1; SMN2 4722/4885MAPT 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.